Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solitary Fibrous Tumors × eribulin × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 15 Liposarcoma 3 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Leiomyosarcoma 2 Breast Neoplasms 2 Solitary Fibrous Tumors 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Melanoma 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pazopanib 2 Ifosfamide 2 Doxorubicin 2 selinexor 1 repotrectinib 1 pembrolizumab 1 eribulin 1 Trabectedin 1 Suspensions 1 Sunitinib 1 Proton Therapy 1 Nivolumab 1 Methotrexate 1 Magnetic Resonance Spectroscopy 1 Histamine H2 Antagonists 1 Fluorodeoxyglucose F18 1 Famotidine 1 FAPI-46 1 Epirubicin 1 Dasatinib 1 Dacarbazine 1 Cisplatin 1 Capsules 1 Angptl4 protein, mouse 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03840772 2024-09-20

ERASING

Italian Sarcoma Group

Phase 2 Completed

Sarcoma, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡